Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Neurology · Autoimmune Brainstem Encephalitis

Treating Autoimmune Brainstem Encephalitis

At a Glance

Autoimmune brainstem encephalitis requires urgent hospital care: doctors first assess for Listeria because steroids can worsen an untreated infection. Once safe, treatment may include high-dose steroids, IVIG, plasma exchange, and treatment of an underlying tumor.

Treating autoimmune brainstem encephalitis is a race against time. Because the brainstem controls vital “autopilot” functions like your heart rate and breathing, doctors aim to calm the immune attack quickly to prevent permanent damage [1][2]. Treatment generally has two goals: modulating the overactive immune system and finding the “trigger”—which is often a hidden tumor [3][4].

The “Safety First” Rule: Rapid Infection Evaluation

Before your doctors can safely suppress your immune system with powerful medications, they must rapidly evaluate whether your symptoms are being caused by a hidden infection.

A bacteria called Listeria can cause rhombencephalitis (inflammation of the hindbrain) that looks almost identical to the autoimmune version [5][6].

  • The Risk: If you have a Listeria infection and receive high-dose steroids, the bacteria can multiply rapidly because the steroids weaken your body’s ability to fight back, leading to severe brain injury or death [7][8].
  • The Protocol: A negative CSF PCR or culture, or the absence of fever, does not reliably exclude Listeria. Because waiting for every test result can be dangerous in a deteriorating patient, specialists often start empiric appropriate antimicrobial treatment (such as ampicillin) while testing is pending. Neurologists and infectious disease clinicians then make a careful, individualized decision about when to safely begin immunotherapy [9][10][11].

First-Line Therapies: The Initial Attack

Once the care team determines it is safe, they will typically start with one or more of these clinician-directed examples of “standard of care” treatments. For this uncommon syndrome, evidence is limited, and treatment choice depends on severity, suspected mechanism, antibody, and infection risk.

  1. High-Dose Corticosteroids: These have broad anti-inflammatory and immune effects, often given as an IV infusion of methylprednisolone (e.g., 1,000 mg daily for 3 to 5 days) [12].
    • Side effects: Hyperglycemia (high blood sugar), significant mood or sleep changes, increased blood pressure, and increased infection risk.
  2. Intravenous Immunoglobulin (IVIG): This is a concentrated mix of healthy antibodies from thousands of donors with several immunomodulatory mechanisms [13]. A common regimen is 2 grams per kilogram of your body weight over several days [14].
    • Side effects: Kidney injury, thrombosis (blood clots), hemolysis, and aseptic meningitis (headaches).
  3. Plasma Exchange (PLEX): Also called plasmapheresis, this process cycles your blood through a machine to remove plasma constituents, rather than selectively removing only harmful antibodies, and replaces it with healthy fluid [13]. It may be used early in severe cases [15][16].
    • Side effects: Bleeding, hypotension (low blood pressure), electrolyte imbalances, and central line infection.

Second-Line Therapies: For Stubborn Cases

If first-line treatments don’t lead to improvement, your doctor may suggest “second-line” medications.

  • Rituximab: This medication depletes CD20-positive B cells (but does not remove all antibody-producing plasma cells) [17]. Risks include infusion reactions, hepatitis B reactivation, and infections.
  • Cyclophosphamide: This is a stronger immune-suppressant often used in severe cases [18][19]. Risks include infertility, bladder toxicity, marrow suppression, and malignancy risk.

Treating the “Trigger” (The Paraneoplastic Link)

If your encephalitis is paraneoplastic—meaning it was triggered by a cancer—treating the tumor is important [3].

  • Combined Effort: Treating the tumor helps control the immune trigger [4][20].
  • Prognosis: While treatment of the tumor (like in KLHL11 cases) is critical for stabilization, neurological injury from intracellular T-cell syndromes may be irreversible, and cancer treatment does not automatically replace the need for immunotherapy [21][22].

Critical Monitoring: Breathing and Swallowing

While the medications work, your care team must strictly monitor your bulbar functions [23].

  • Aspiration Prevention: Because the brainstem controls your throat muscles, you may need a temporary feeding tube or a modified diet to prevent food or saliva from entering your lungs [23][1].
  • Airway Support: If your breathing becomes irregular, you may require close CO2/oxygen monitoring or a stay in the Intensive Care Unit (ICU) for respiratory support [12][13].

What to expect in the hospital: Your timeline will include emergency assessment, MRI/lumbar puncture, empiric infection coverage, antibody testing, acute immunotherapy, and extensive physical/swallow rehabilitation planning. Early and appropriate treatment gives the best chance for stabilization [1][2].

Common questions in this guide

Why do doctors check for Listeria before giving steroids?
Listeria infection can cause brainstem inflammation that looks like the autoimmune illness. Steroids weaken immune defenses, so they can allow an untreated Listeria infection to spread and cause severe harm. Early testing and the absence of fever may not fully rule it out, so clinicians may give ampicillin while tests are pending.
What treatments are usually used first for autoimmune brainstem encephalitis?
After infection risk has been assessed, clinicians may use high-dose intravenous steroids, IVIG, plasma exchange, or a combination of these treatments. The choice depends on the illness severity, antibody findings, suspected immune mechanism, and infection risk.
What happens if initial treatment does not improve the encephalitis?
Specialists may consider rituximab or cyclophosphamide as second-line treatment. These medicines suppress parts of the immune system and can cause serious side effects, so the care team must weigh their potential benefits and risks.
Could a tumor be causing autoimmune brainstem encephalitis?
Yes, some cases are paraneoplastic, meaning that a cancer triggers the immune response. Finding and treating the cancer can help control the trigger, but it may not reverse established neurological injury, and immune treatment may still be needed.
Why are swallowing and breathing monitored so closely?
Brainstem inflammation can weaken the muscles used for swallowing and breathing. A modified diet or temporary feeding tube may reduce the risk of food or saliva entering the lungs, while oxygen and carbon dioxide monitoring or intensive care support may be needed if breathing becomes irregular.
What should I expect during hospital treatment?
Hospital care may include an MRI, a lumbar puncture, infection testing, antibody testing, and antibiotics started before all results return when Listeria is a concern. Once the team determines that immune treatment is safe, therapy may begin alongside breathing, swallowing, physical, and rehabilitation monitoring.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Non-specific autoimmune brainstem encephalitis with characteristic antibodies.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How are infectious disease and neurology working together to manage my evaluation for Listeria while deciding on immunotherapy?
  2. 2.Which of the first-line treatments (steroids, IVIG, or PLEX) do you recommend starting with as an example, and why?
  3. 3.At what point will we decide to move to second-line therapies like Rituximab or Cyclophosphamide?
  4. 4.If a tumor is found, how will my oncology team and neurology team coordinate the timing of my cancer treatment and my immunotherapy?
  5. 5.What specific monitoring is in place to ensure I am breathing safely at night and not at risk for silent aspiration?

References

References (23)
  1. 1

    Autoimmune brainstem encephalitis: Clinical associations, outcomes, and proposed diagnostic criteria.

    Gilligan M, Thakolwiboon S, Orozco E, et al.

    Annals of clinical and translational neurology 2025; (12(1)):213-225 doi:10.1002/acn3.52273.

    PMID: 39708293
  2. 2

    Treatment strategies for autoimmune encephalitis.

    Shin YW, Lee ST, Park KI, et al.

    Therapeutic advances in neurological disorders 2018; (11()):1756285617722347 doi:10.1177/1756285617722347.

    PMID: 29399043
  3. 3

    Paraneoplastic Myeloneuropathies: Clinical, Oncologic, and Serologic Accompaniments.

    Shah S, Vazquez Do Campo R, Kumar N, et al.

    Neurology 2021; (96(4)):e632-e639 doi:10.1212/WNL.0000000000011218.

    PMID: 33208548
  4. 4

    Clinical Manifestations, Tumor Associations, and Long-Term Outcomes of Anti-KLHL11 Encephalitis.

    Jin M, Brand T, Erdag Turgeon E, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2026; (13(4)):e200597 doi:10.1212/NXI.0000000000200597.

    PMID: 42214057
  5. 5

    Clinical Presentation and Cranial MRI Findings of Listeria monocytogenes Encephalitis: A Literature Review of Case Series.

    Arslan F, Ertan G, Emecen AN, et al.

    The neurologist 2018; (23(6)):198-203 doi:10.1097/NRL.0000000000000212.

    PMID: 30379745
  6. 6

    Listeria rhombencephalitis mimicking a demyelinating event in an immunocompetent young patient.

    Décard BF, Thöne J, Haghikia A, et al.

    Multiple sclerosis (Houndmills, Basingstoke, England) 2017; (23(1)):123-125 doi:10.1177/1352458516650522.

    PMID: 27430683
  7. 7

    Rhombencephalitis due to Listeria monocytogenes infection with GQ1b antibody positivity and multiple intracranial hemorrhage: a case report and literature review.

    Zhao Y, Xu C, Tuo H, et al.

    The Journal of international medical research 2021; (49(4)):300060521998568 doi:10.1177/0300060521998568.

    PMID: 33866842
  8. 8

    Listeria rhombencephalitis mimicking stroke in a patient with giant cell arteritis.

    Shimizu H, Imoto H, Hara S, Nishioka H

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2023; (29(7)):703-706 doi:10.1016/j.jiac.2023.03.016.

    PMID: 36996936
  9. 9

    Listerial rhombencephalitis diagnosed by repeat blood culture despite negative CSF PCR: a case report.

    Arientová S, Galušková R, Ceprová L, et al.

    ASM case reports 2026; (2(5)) doi:10.1128/asmcr.00063-26.

    PMID: 42683398
  10. 10

    Analysis of a case report of meningitis caused by Listeria monocytogenes.

    Chen L, Pei M, Wang X, et al.

    Frontiers in medicine 2024; (11()):1440225 doi:10.3389/fmed.2024.1440225.

    PMID: 39323466
  11. 11

    Epidemiology and Clinical Manifestations of Listeria monocytogenes Infection.

    Schlech WF

    Microbiology spectrum 2019; (7(3)) doi:10.1128/microbiolspec.GPP3-0014-2018.

    PMID: 31837132
  12. 12

    First case report on Bickerstaff brainstem encephalitis in a young adult from Syria: Bridging clinical knowledge and practice.

    Almohamed A, Qatza A, Alsamman H, et al.

    Radiology case reports 2025; (20(2)):1211-1214 doi:10.1016/j.radcr.2024.11.006.

    PMID: 39697258
  13. 13

    A unified spectrum model for the anti-GQ1b antibody syndromes: from pathophysiology to a new diagnostic framework.

    El Abdi K, Bibi F, Ibrahim M, et al.

    Frontiers in neurology 2026; (17()):1763283 doi:10.3389/fneur.2026.1763283.

    PMID: 42093930
  14. 14

    ImmunoglobuliN in the Treatment of Encephalitis (IgNiTE): protocol for a multicentre randomised controlled trial.

    Iro MA, Sadarangani M, Absoud M, et al.

    BMJ open 2016; (6(11)):e012356 doi:10.1136/bmjopen-2016-012356.

    PMID: 27810972
  15. 15

    Anti-GQ1b Antibody Syndrome: A Clinician-Oriented Perspective on Diagnostics, Therapy, and Atypical Phenotypes-With an Illustrative 16-Case Institutional Series.

    Bannai T, Yamada M, Seki T, et al.

    Journal of clinical medicine 2026; (15(2)) doi:10.3390/jcm15020801.

    PMID: 41598737
  16. 16

    Modified Zipper Method, a Promising Treatment Option in Severe Pediatric Immune-Mediated Neurologic Disorders.

    Nikolaus M, Kühne F, Tietze A, et al.

    Journal of child neurology 2022; (37(6)):505-516 doi:10.1177/08830738221089476.

    PMID: 35435761
  17. 17

    Multiple co-existing antibodies in autoimmune encephalitis: A case and review of the literature.

    Kammeyer R, Piquet AL

    Journal of neuroimmunology 2019; (337()):577084 doi:10.1016/j.jneuroim.2019.577084.

    PMID: 31655424
  18. 18

    Brainstem Encephalitis in Neuropsychiatric Systemic Lupus Erythematosus Mimicking Malignant Lymphoma: A Case Report and Literature Review.

    Ueno T, Ochiai S

    Cureus 2026; (18(1)):e101551 doi:10.7759/cureus.101551.

    PMID: 41694957
  19. 19

    Systemic lupus erythematosus with hypothermia and Wallenberg's syndrome as signs of brainstem encephalitis: A grand rounds case.

    Shiratani R, Shibahara T, Shiba M, et al.

    Lupus 2025; (34(5)):525-532 doi:10.1177/09612033251324496.

    PMID: 40010374
  20. 20

    Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy.

    Zekeridou A, Lennon VA

    Mayo Clinic proceedings 2019; (94(9)):1865-1878 doi:10.1016/j.mayocp.2019.02.003.

    PMID: 31358366
  21. 21

    Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis.

    Dubey D, Wilson MR, Clarkson B, et al.

    JAMA neurology 2020; (77(11)):1420-1429 doi:10.1001/jamaneurol.2020.2231.

    PMID: 32744608
  22. 22

    Pathogenesis, diagnosis and treatment of paraneoplastic neurologic syndromes.

    Blaes F

    Expert review of neurotherapeutics 2021; (21(6)):675-686 doi:10.1080/14737175.2021.1927713.

    PMID: 33960258
  23. 23

    Brainstem Encephalitis With Low-Titer Acetylcholine Receptor Antibodies Mimicking Myasthenia Gravis.

    Ayzenberg I, Ellrichmann G, Schroeder C, et al.

    Frontiers in neurology 2019; (10()):829 doi:10.3389/fneur.2019.00829.

    PMID: 31428040

This page is for informational purposes only and does not constitute medical advice. Decisions about infection treatment, immunotherapy, and breathing or swallowing support should be made with your neurology and infectious disease teams.